Related references
Note: Only part of the references are listed.Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension
Christopher J. Rhodes et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial
Steeve Provencher et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension
Lars Harbaum et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)
Marc Humbert et al.
EUROPEAN HEART JOURNAL (2022)
A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension
A. Josien Smits et al.
ERJ OPEN RESEARCH (2022)
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
Marc A. Simon et al.
PULMONARY CIRCULATION (2022)
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
Raymond L. Benza et al.
CHEST (2021)
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Kelly M. Chin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Marc Humbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Marius M. Hoeper et al.
LANCET RESPIRATORY MEDICINE (2021)
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension A Double-Blind Placebo-controlled Clinical Trial
R. James White et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Inhibition of serotonin synthesis: A novel therapeutic paradigm
Michael Bader
PHARMACOLOGY & THERAPEUTICS (2020)
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
Olivier Sitbon et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
Lai-Ming Yung et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study
Adetoun Sodimu et al.
PULMONARY CIRCULATION (2020)
New and Emerging Therapies for Pulmonary Arterial Hypertension
Edda Spiekerkoetter et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Predicting Survival in Patients With Pulmonary Arterial Hypertension The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies
Raymond L. Benza et al.
CHEST (2019)
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial
Fernando Torres et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension
Khodr Tello et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension
Ivana Nikolic et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
An overview of the 6th World Symposium on Pulmonary Hypertension
Nazzareno Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives
Marc Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Gerald Simonneau et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension
David Kylhammar et al.
EUROPEAN HEART JOURNAL (2018)
Risk Assessment Tools in Pulmonary Arterial Hypertension Prognosis for Prospective Trials?
Harrison W. Farber et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
The Low-Risk Profile in Pulmonary Arterial Hypertension Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
Jason Weatherald et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
Nabham Rai et al.
BIOMED RESEARCH INTERNATIONAL (2018)
The comings and goings of PARP-1 in response to DNA damage
John M. Pascal
DNA REPAIR (2018)
Inhibitory Antibodies against Activin A and TGF-beta Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension
Tatiana V. Kudryashova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
Marc Humbert et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Marius M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Marius M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension
Edda Spiekerkoetter et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects
Xinping Chen et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
Athenais Boucly et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension
Lai-Ming Yung et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
World Health Organization Group I Pulmonary Hypertension Epidemiology and Pathophysiology
Kurt W. Prins et al.
CARDIOLOGY CLINICS (2016)
Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension
Laurent Calvier et al.
HEART (2016)
Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension
Yi Yan et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Bone Morphogenetic Protein Receptor Type II Deficiency and Increased Inflammatory Cytokine Production
Elaine Soon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension
Benoit Ranchoux et al.
CIRCULATION (2015)
Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension
Francois Potus et al.
CIRCULATION (2015)
Bromodomain-Containing Protein 4 The Epigenetic Origin of Pulmonary Arterial Hypertension
Jolyane Meloche et al.
CIRCULATION RESEARCH (2015)
Validation of two predictive models for survival in pulmonary arterial hypertension
Olivier Sitbon et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension
Adaani E. Frost et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2015)
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Tetsuo Asaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Mitochondrial dynamics in pulmonary arterial hypertension
John Ryan et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2015)
Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
Lu Long et al.
NATURE MEDICINE (2015)
ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension
Hailong Dai et al.
NATURE REVIEWS CARDIOLOGY (2015)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
N. Galie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Iloprost reverses established fibrosis in experimental right ventricular failure
Jose Gomez-Arroyo et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload
Marinus A. Borgdorff et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Impaired Angiogenesis and Peripheral Muscle Microcirculation Loss Contribute to Exercise Intolerance in Pulmonary Arterial Hypertension
Francois Potus et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Sex-Dependent Influence of Endogenous Estrogen in Pulmonary Hypertension
Kirsty M. Mair et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Role for DNA Damage Signaling in Pulmonary Arterial Hypertension
Jolyane Meloche et al.
CIRCULATION (2014)
Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first
Sylvia Cohen-Kaminsky et al.
DRUG DISCOVERY TODAY (2014)
Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension
Vinayak Shenoy et al.
HYPERTENSION (2014)
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
Gerald Simonneau et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
Georgia Pitsiou et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension
Abdallah Alzoubi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2013)
Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models
Vinayak Shenoy et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Ghrelin and Its Relation with N-Terminal Brain Natriuretic Peptide, Endothelin-1 and Nitric Oxide in Patients with Idiopathic Pulmonary Hypertension
Dan Yang et al.
CARDIOLOGY (2013)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
Zhi-Cheng Jing et al.
CIRCULATION (2013)
Transforming Growth Factor-β Signaling Promotes Pulmonary Hypertension Caused by Schistosoma Mansoni
Brian B. Graham et al.
CIRCULATION (2013)
The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension
Nada Kherbeck et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2013)
FK506 activates BMPR2 rescues endothelial dysfunction, and reverses pulmonary hypertension
Edda Spiekerkoetter et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Pulmonary Arterial Hypertension Epidemiology and Registries
Michael D. McGoon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Rubin M. Tuder et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Pulmonary arterial hypertension: a flavor of autoimmunity
Frederic Perros et al.
M S-MEDECINE SCIENCES (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pulmonary arterial hypertension
David Montani et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Signal transduction in the development of pulmonary arterial hypertension
Simon Malenfant et al.
PULMONARY CIRCULATION (2013)
Dysregulated Renin-Angiotensin-Aldosterone System Contributes to Pulmonary Arterial Hypertension
Frances S. de Man et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland
Yi Ling et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Validation of the Pulmonary Hypertension Connection Equation for Survival Prediction in Pulmonary Arterial Hypertension
Thenappan Thenappan et al.
CHEST (2012)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study) A Randomized Controlled Trial
Victor E. Tapson et al.
CHEST (2012)
The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension
Raymond L. Benza et al.
CHEST (2012)
Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle
Marinus A. J. Borgdorff et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Predicting survival in pulmonary arterial hypertension in the UK
Wai-Ting Nicola Lee et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Molecular pathogenesis of pulmonary arterial hypertension
Marlene Rabinovitch
JOURNAL OF CLINICAL INVESTIGATION (2012)
BMPR2 expression is suppressed by signaling through the estrogen receptor
Eric D. Austin et al.
BIOLOGY OF SEX DIFFERENCES (2012)
Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension The SUPER-2 Study
Lewis J. Rubin et al.
CHEST (2011)
The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States How REVEAL Differs From Historic and Non-US Contemporary Registries
Adaani E. Frost et al.
CHEST (2011)
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Johannes-Peter Stasch et al.
CIRCULATION (2011)
Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension
W-T. N. Lee et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
Robyn J. Barst et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation
Laurence Dewachter et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Why Doesn't Imatinib Cure Chronic Myeloid Leukemia?
Robert L. Redner
ONCOLOGIST (2010)
American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer
Harold J. Burstein et al.
JOURNAL OF ONCOLOGY PRACTICE (2010)
Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart
M. Handoko et al.
EUROPEAN RESPIRATORY REVIEW (2010)
Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline
Matthew Thomas et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease
Lu Long et al.
CIRCULATION (2009)
Dehydroepiandrosterone Reverses Systemic Vascular Remodeling Through the Inhibition of the Akt/GSK3-β/NFAT Axis
Sebastien Bonnet et al.
CIRCULATION (2009)
Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
A. Lavelle et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Elevated levels of activin A in clinical and experimental pulmonary hypertension
Arne Yndestad et al.
JOURNAL OF APPLIED PHYSIOLOGY (2009)
Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-β-catenin and Wnt-RhoA-Rac1 pathways
Vinicio A. de Jesus Perez et al.
JOURNAL OF CELL BIOLOGY (2009)
Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Ronald J. Oudiz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Genetics and Genomics of Pulmonary Arterial Hypertension
Rajiv D. Machado et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Inflammation, Growth Factors, and Pulmonary Vascular Remodeling
Paul M. Hassoun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Epigenetics: Definition, Mechanisms and Clinical Perspective
Catherine Dupont et al.
SEMINARS IN REPRODUCTIVE MEDICINE (2009)
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension
Frederic Perros et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system
Daniel W. Lambert et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice
Yvonne Dempsie et al.
CIRCULATION (2008)
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Christian F. Opitz et al.
EUROPEAN HEART JOURNAL (2008)
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Marc Iglarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension
Marc Humbert et al.
VASCULAR PHARMACOLOGY (2008)
Results of European post-marketing surveillance of bosentan in pulmonary hypertension
M. Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2007)
Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Gαi protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression
Dongmin Liu et al.
ENDOCRINOLOGY (2007)
Cardioprotective prostacyclin signaling in vascular smooth muscle
Kristina M. Fetalvero et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension
Richard N. Channick et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension
Derliz Mereles et al.
CIRCULATION (2006)
N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension
Arne K. Andreassen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension
Anna Fijalkowska et al.
CHEST (2006)
Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival - Implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension
K Teichert-Kuliszewska et al.
CIRCULATION RESEARCH (2006)
Dominant negative mutation of the TGF-β receptor blocks hypoxia-induced pulmonary vascular remodeling
YF Chen et al.
JOURNAL OF APPLIED PHYSIOLOGY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reversal of experimental pulmonary hypertension by PDGF inhibition
RT Schermuly et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension
CF Opitz et al.
EUROPEAN HEART JOURNAL (2005)
Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension
SL Merklinger et al.
CIRCULATION (2005)
Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats
C Guignabert et al.
CIRCULATION (2005)
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist
CD Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor
DM Liu et al.
STEROIDS (2004)
Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management
ETH Yeh et al.
CIRCULATION (2004)
Differential effects of TGF-β1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells
KKK Sheares et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension
E Marcos et al.
CIRCULATION RESEARCH (2004)
Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension
H Olschewski et al.
CHEST (2003)
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension
E Marcos et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension
S Bonnet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Assessment of the vasodilator response in primary pulmonary hypertension - Comparing prostacyclin and iloprost administered by either infusion or inhalation
CF Opitza et al.
EUROPEAN HEART JOURNAL (2003)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor
C Atkinson et al.
CIRCULATION (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
RN Channick et al.
LANCET (2001)
DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology
F Labrie et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2001)
NO-independent regulatory site on soluble guanylate cyclase
JP Stasch et al.
NATURE (2001)
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
JR Thomson et al.
JOURNAL OF MEDICAL GENETICS (2000)
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
ZM Deng et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
Share Paper
